Quick Answer
Aldeyra Therapeutics, Inc. reported Research And Development Expense of $25.66 million for the year ending 2025.
- Aldeyra Therapeutics, Inc. showed a decrease of -46.8% in Research And Development Expense from 2024 to 2025.
- This data is from Aldeyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Aldeyra Therapeutics, Inc.'s Research And Development Expense has grown by 1,564.6%.
- Historical annual values: Fiscal year 2025: $25.66 million | Fiscal year 2024: $48.22 million | Fiscal year 2023: $29.46 million | Fiscal year 2022: $47.31 million | Fiscal year 2021: $44.94 million | Fiscal year 2020: $24.68 million | Fiscal year 2019: $44.35 million | Fiscal year 2018: $29.82 million | Fiscal year 2017: $16.30 million | Fiscal year 2016: $13.18 million | Fiscal year 2015: $7.57 million | Fiscal year 2014: $3.71 million | Fiscal year 2013: $1.54 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: